AMAG Pharmaceuticals Inc (AMAG)

18.80
NASDAQ : Health Care
Prev Close 18.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 16.00 / 36.83
Avg Volume 811.90K
Exchange NASDAQ
Shares Outstanding 35.29M
Market Cap 672.24M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AMAG Announces U.S. FDA Filing Acceptance And Six-Month Review Of Feraheme® (ferumoxytol) For The Treatment Of All Adult Patients With Iron Deficiency Anemia

AMAG Announces U.S. FDA Filing Acceptance And Six-Month Review Of Feraheme® (ferumoxytol) For The Treatment Of All Adult Patients With Iron Deficiency Anemia

Prescription Drug User Fee Act (PDUFA) Target Action Date of February 2, 2018 Established

AMAG Pharmaceuticals Stock Sees Short Interest Fall 15.7%

AMAG Pharmaceuticals Stock Sees Short Interest Fall 15.7%

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,611,369 share decrease in total short interest for AMAG Pharmaceuticals, Inc. , to 8,685,429, a decrease of 15.65% since 07/31/2017.

Commit To Purchase AMAG Pharmaceuticals At $16, Earn 16.7% Annualized Using Options

Commit To Purchase AMAG Pharmaceuticals At $16, Earn 16.7% Annualized Using Options

Investors considering a purchase of AMAG Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $19.05/share, might benefit from considering selling puts among the alternative strategies at their disposal.

AMAG Pharmaceuticals is Now Oversold (AMAG)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AMAG Pharmaceuticals Completes Financing Transactions In Support Of Future Growth Strategy

Transactions extend maturities and reduce total debt by approximately 18%

Bearish Bets: A Big Biotech, a Computing Legend and Other Stocks That Look Good Short

AMAG, ETM, HYH, CRAY and INCY all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, AVD, BCC, BGSF, CDR, CTRE, DV, LUK, PHX, PRLB, RTIX, SFM, STAY, TRP, WAGE, ZAGG Downgrades: ABCO, ACIW, AMAG, CQP, HDNG, INT, NEWM, RGS, SGEN, SSP, TAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AMAG Pharmaceuticals is Now Oversold (AMAG)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Luminex, Exelixis, AMAG Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

TheStreet Quant Rating: D+ (Sell)